Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani, Cristina Papayannidis, Jessica T. Leonard, Maria R. Baer, Josep-Maria Ribera, James McCloskey, JianXiang Wang, Sujun Gao, Deepali Rane, Shien Guo

Blood (2024) 144 (Supplement 1): 2825.

https://doi.org/10.1182/blood-2024-208755

Published: 2024

Journal Articles

Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial

Christopher G. Pelligra, Fjoralba Kristo, Yutian Mu, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2024-200133

Published: 2024

Journal Articles

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial

Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, Antoine Regnault, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2024-200211

Published: 2024

Journal Articles

Results from a Systematic Review of Advanced-Stage Hodgkin Lymphoma Treatments and a Matching-Adjusted Indirect Treatment Comparison of A+AVD vs PET-Guided ABVD

Fjoralba Kristo, Alexa Molinari, Zhiyi Lan, Victoria Federico Paly, Ramsha Khan, Abbey Poirier, Christina Soeun Kwon, Hoora Moradian, Bipin N. Savani, Athanasios Zomas, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 7752.

https://doi.org/10.1182/blood-2024-201001

Published: 2024

Journal Articles

Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, Antoine Regnault, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2024-200233

Published: 2024

Journal Articles

The Comparative Effectiveness of A+AVD vs PET-guided ABVD for the Management of Patients with Advanced Hodgkin Lymphoma: A Systematic Review and Matching-Adjusted Indirect Treatment Comparison

Fjoralba Kristo, Victoria Federico Paly, Katherine Fazioli, Conor McCloskey, Sunita Nair, Bipin N. Savani, Athanasios Zomas, Ajibade Ashaye

Blood (2023) 142 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2023-174845

Published: 2023

Journal Articles

Real-World Treatment Patterns and Patient Outcomes in Relapsed/Refractory Hodgkin Lymphoma in the US

Fjoralba Kristo, Melissa Lingohr-Smith, Jay Lin, Ajibade Ashaye

Blood (2023) 142 (Supplement 1): 7347.

https://doi.org/10.1182/blood-2023-174435

Published: 2023

Journal Articles

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Ajibade Ashaye, Yves Chalandon, Hervé Dombret, Katherine Fazioli, Bingxia Wang, Ibrahim Aldoss, Fei Huang, Jessica T. Leonard, Nora Szabo, Conor McCloskey, Sunita Nair, Mehul Dalal, Meliessa Hennessy, Tammie Yeh, Talha Badar, Hagop Kantarjian, Josep-Maria Ribera, Elias Jabbour

Blood (2023) 142 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2023-179645

Published: 2023

Journal Articles

Comparative Efficacy and Safety of Gemtuzumab Ozogamicin (GO) Plus Daunorubicin-Cytarabine Combination and Comparators As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Ajibade Ashaye, Zarmina S. Khankhel, Yingxin Xu, Kyle Fahrbach, PhD, Ruth Mokgokong, Michelle Orme, Kathryn Lang, Joseph C. Cappelleri, PhD MPH, MS, Carla M. Mamolo

Blood (2017) 130 (Supplement 1): 2103.

https://doi.org/10.1182/blood.V130.Suppl_1.2103.2103

Published: 2017

NARROW

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial

Results from a Systematic Review of Advanced-Stage Hodgkin Lymphoma Treatments and a Matching-Adjusted Indirect Treatment Comparison of A+AVD vs PET-Guided ABVD

Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

The Comparative Effectiveness of A+AVD vs PET-guided ABVD for the Management of Patients with Advanced Hodgkin Lymphoma: A Systematic Review and Matching-Adjusted Indirect Treatment Comparison

Real-World Treatment Patterns and Patient Outcomes in Relapsed/Refractory Hodgkin Lymphoma in the US

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Comparative Efficacy and Safety of Gemtuzumab Ozogamicin (GO) Plus Daunorubicin-Cytarabine Combination and Comparators As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only